“ArkBio is dedicated to drug development for RSV treatment that is represented ... posing a significant threat to children under five years. It also increases the risk of asthma and recurrent ...

An Australian-first study demonstrating the effectiveness of a new immunization against respiratory syncytial virus (RSV) for ...

The investigational monoclonal antibody clesrovimab protected against respiratory syncytial virus (RSV ... additional 3,334 ...

Nirsevimab-resistant respiratory syncytial virus variants remain rare, but continued molecular surveillance is crucial. Read ...

Despite the heavy RSV-related burden in infants, effective vaccines or medications for infants are not available. Although palivizumab, a monoclonal antibody (mAb), provides protection ...

Nearly three fourths of infants born during the 2023-2024 respiratory syncytial virus (RSV) season received protection with either nirsevimab or exposure to maternal RSVpreF, with maternal RSVpreF ...

It is estimated that an average of 33 children under five years old die from RSV in the UK each year 7. There is no effective specific drug treatment for RSV and as a result, the mainstay of ...

A new study utilizing next-generation sequencing reveals high RSV co-infection rates in hospitalized children, underscoring ...

as a one-dose preventative treatment to protect infants born during or entering their first RSV season from lower respiratory tract infection (LRTI) with the virus. It is the first RSV prevention ...

In primary care settings, the burden of RSV on young children and their guardians often varied between the countries of ...